Posts

Showing posts from August, 2010

PhD POSITION @ TIFR

http://univ.tifr.res.in/gs2011/Files/Advertisement.pdf Share |

Roche Enters $1.1B Drug Deal With US's Aileron Therapeutics for New Stapled Peptide Therapeutics

Aileron Therapeutics and Roche announced today that they have entered into a collaboration to discover, develop and commercialise a new class of drugs called Stapled Peptide Therapeutics. As part of this agreement, Roche will work with Aileron to develop drug candidates against up to five undisclosed targets selected from Roche’s key therapeutic areas, which include oncology, virology, inflammation, metabolism and CNS. Stapled Peptide Therapeutics are a result of Aileron’s breakthrough peptide stabilization technology, and are a potential solution to drug as-yet intractable disease targets, including those originating from long sought-after intracellular protein-protein interactions. Under the terms of the agreement, Roche will provide Aileron guaranteed funding of at least $25 million in technology access fees and R&D support. Aileron is eligible to receive up to $1.1 billion in payments upon the achievement of discovery, development, regulatory and commercialisation milesto

Life Technologies to Acquire Ion Torrent for up to $725M

Life Technologies announced after the close of the market Tuesday that it will acquire sequencing technologies startup Ion Torrent Systems for $375 million in cash and stock. The total value of the deal could rise by another $350 million if certain technical and time-based milestones are met through 2012. Ion Torrent has developed the Personal Genome Machine, a benchtop instrument that is currently being used by early-access customers and will be launched later this year at an entry cost of less than $100,000. The system will be "optimal for mid-scale sequencing projects, such as targeted and microbial sequencing. The transaction is expected to be dilutive by $.02 for Life Tech's earnings per share in 2010, and neutral to earnings in 2011. It is expected to be accretive in 2012 and beyond. Life Tech said that its EPS guidance for FY 2010 remains unchanged at $3.35 to $3.50. The firms expect to close the transaction in the fourth quarter of this year. in early Wednesday trade

Position @ Sheba Cancer Research Center Israel

Courtesy Bioclues The growing bioinformatics unit in the Cancer Research Center in Sheba medical center (Tel Hashomer) is looking for a PhD student and a bioinformatician (see attachments). The Cancer Research Center is equipped with state of the art technologies for high throughput data analysis, including Solexa sequencing machine. We also have the benefits of close access to clinical and diagnostics data. All making it a gold mine for bioinformaticans. The bioinformatics unit in the Sheba cancer research cancer is seeking for a bioinformatican. The projects involve programming and usage of advanced bioinformatics tools and include analysis of deep sequencing data. Contact:   eran.eyal@sheba.health.gov.il ,  972- 03-5308148 Share |

Position @ Strand LS, Scientific Writer, Marketing & Communications

Position Title:  Scientific Writer, Marketing & Communications Reporting To:  Director Marketing and Communications Business Area:  Marketing and Communications Job Description: This position requires varied writing skills for interpreting diverse scientific data into easily readable information, such as. •    Developing written materials, including, content for the websites, blogs, communities,  brochures, flyers, case studies, whitepapers, newsletters, press releases, Q&A, presentations and speeches, tech journals, etc. Proficiency in succinctly writing “benefit-oriented” copy that breaks through and strikes a chord with the reader. •    Creating written communications for all corporate collateral needs, including but not limited to tradeshow displays, website, blogs, brochures and trade advertising, •    Contributing actively to the concept, structure and contents of corporate literature and online projects •    Playing an active role in implementing glo

Bioinformatics education in India

Image
An account of  bioinformatics  education in India is presented   along with future prospects. Establishment of BTIS network by   Department of Biotechnology (DBT), Government of India in the   1980s had been a systematic effort in the development of  bioinformatics   infrastructure in India to provide services to scientific community.   Advances in the field of  bioinformatics  underpinned the need   for well-trained professionals with skills in information technology   and biotechnology. As a result, programmes for capacity building   in terms of human resource development were initiated. Educational   programmes gradually evolved from the organisation of short-term   workshops to the institution of formal diploma/degree programmes.   A case study of the Master’s degree course offered at   the  Bioinformatics  Centre, University of Pune is discussed.   Currently, many universities and institutes are offering  bioinformatics   courses at different levels with variations in the course c

Protein Structure and Drug Discovery Workshop

"Protein Structure and Drug Discovery" Workshop – Sept 30th to Oct 1st 2010 La Jolla, CA. Please join us at MolSoft's (   www.molsoft.com   ) "Protein Structure and Drug Design" Workshop in La Jolla, California USA. For more information and a registration form see:   www.molsoft.com/training.html This workshop is suitable for chemists and biologists who would like to learn more about computational drug discovery and bioinformatics. No prior knowledge in this field is required to participate. The workshop is presented by Prof. Ruben Abagyan (University of California San Diego) and Dr. Maxim Totrov (MolSoft). Price: $349 (Academics) $749 (Commercial) The workshops will consist of lectures, demonstrations, and "hands-on" computational experiments and will cover the following topics: - How To Display Fully Interactive 3D Molecules in PowerPoint and the Web - Sequence and Protein Structure Analysis - Protein Modeling and Simulations - Structure

Post-doc@Harvard Medical School

Organization:  Harvard Medical School Job Location:  Harvard Medical School, Boston, Massachusetts, USA Salary:  $50,000/year Benefits:  Family health insurance, T-Pass discount, credit union, child-care scholarships Job Description:  Post-doctoral position.Available immediately. Permanent residency not required. Working at the interface of biology, statistics, and computing, the candidate will analyze high through-put gene expression microarray data in cancer genomics. The goal is to develop novel data analysis algorithms and software and to identify genomic signatures in cancer patients and tumor-bearing mice. Requirements:  Qualifications: (i) PhD in bioinformatics, biostatistics, computer science or related fields; (ii)familiarity with molecular biology and genomics; (iii)strong programming skills (R, C++, Python): and (iv) proficiency in microarray software Bioconductor, dChip, and GenePattern. Contact Information:  Please send CV, a career statement, and three letters of

National Seminar on "Computational Biology"

National Seminar on "Computational Biology" September 15-17, 2010. The 3-day seminar will focus on current topics in bioinformatics. Experts in various areas will deliver lectures and conduct demo-sessions. The seminar will be very useful to the faculty and students interested in Bioinformatics. Limited Lab sessions will be provided for 2 days.   http://reg.bicpu.edu.in/ Share |

EBI–Sanger Postdoctoral (ESPOD) Programme

Two ESPOD fellowships available in 2010 The EBI and Wellcome Trust Sanger Institute share the Wellcome Trust Genome Campus. This proximity fosters close collaborations and contributes to an international and vibrant campus environment. Researchers are supported by easy access to scientific expertise, well-equipped facilities and an active seminar programme. The EBI–Sanger Postdoctoral (ESPOD) Programme builds on the strong collaborative relationship between the two institutes, offering projects which combine experimental (wet lab) and computational approaches. Projects may be selected from the areas defined below or proposed by the applicant. In the case of self-defined projects, the area of work must have been agreed with both the EBI- and Sanger-based group leaders. Two postdoctoral fellowships will be awarded in 2010, to start as soon as possible after October 2010 but within 12 months of the fellowship being awarded. Available projects Birney / Semple : Integrated high resolu

CambridgeSoft's Business Partner in Hyderabad, India is hiring for multiple positions

Image
CambridgeSoft's Business Partner in Hyderabad, India is hiring for multiple positions. Appropriate candidates, with a chemistry or biochemistry background, could apply. The following is a list of available positions: Lead Developer - ChemDraw product on a Java platform (Hyderabad, India) Developer - JAVA DEVELOPERS (Hyderabad, India) Lead Developer - Desktop - ChemBio3D (Hyderabad, India) Developer - Enterprise - Network Communication and Distributed Computing (Hyderabad, India) Developer - Desktop - User Interface (Hyderabad, India) Developer - Desktop - Numerical Methods (Hyderabad, India) Lead Developer - Enterprise - Inventory (Hyderabad, India) Lead Developer - Enterprise (Hyderabad, India) Developer - Enterprise - (C++) (Hyderabad India) Developer - Enterprise - E-Notebook Support Analyst (Hyderabad, India) Developer - Desktop - ChemDraw (Hyderabad, India) Lead Developer - Enterprise - E-Notebook (Hyderabad, India) Developer - Enterprise - Database Specialist (

The 4th Virtual Training Workshop on Bioinformatics

The 4th Virtual Training Workshop on Bioinformatics will be held on September-October, 2010, which is organized by Asian Bioinformatics Research and Education Network (ABREN). You are welcome to join the workshop. It covers more useful lectures on bioinformatics. The registration procedure is simple. Just you click the link which attached bellow. They will enable the accounts and send you e-mail with the account information, just before the workshop starts.  Workshop and registration site:  http://www.abren.net/ workshop/ Share |

Java Developer - Bioinformatics

Job Title:  Java Developer - Bioinformatics Salary:  35000-45000 Per Annum Excellent benefits Location:  Surrey Description:  Java Developer, Permanent, Guildford, £35-45k + excellent benefits and package Is a leading software solutions company for the pharmaceutical industry. A new opportunity has become available for a Java Developer with Bioinformatics to join a dedicated team to help develop software solutions to accelerate the drug discovery process. Key responsibilities include: Designing and implementing new products; maintenance work on existing products; mentoring other developers; helping to evangelize technology and component use throughout the company. The successful candidate will be a Java developer with a strong understanding of Bioinformatics. The ideal candidate will also have a working knowledge of J2EE/ JBOSS, Java Swing, JavaScript libraries and SQL but this is a nice to have. Please contact Tom Hildreth for immediate consideration and full company detai

Two interesting bids on the billboard Genzyme and Ascendis Pharma

Courtesy Bloomberg Sanofi-Aventis  may begin a hostile bid for Genzyme Corp. should the U.S. biotechnology company resist a takeover approach, analysts at Citigroup Inc. said. No other bidder is likely to emerge for Cambridge, Massachusetts-based Genzyme, and Sanofi will probably succeed in acquiring the company for $74 to $77 a share, Citigroup analysts  Mark Dainty  and  Yaron Werber  wrote in a report to clients today. Genzyme is worth $70 a share based on estimated cash flow, and Sanofi would benefit from as much as $5.50 a share of synergies in an acquisition, they said. Investors in Genzyme say Paris-based Sanofi may have to pay at least $80 a share, or $21.3 billion, to acquire the maker of drugs that fight genetic diseases. Sanofi Chief Executive Officer  Chris Viehbacher  has support from his board to offer as much as $70 a share, or about $18.7 billion, and is preparing a formal offer letter, three people familiar with the situation said last week. Novo Nordisk A/S, Novar